CDKN2A and cancer: p16/ki-67 positive rate significantly increased with the severity of the cytological lesions from 10.8% (22/207) in NILM to 92.9% (13/14) in patients with cancers (SCC+ADC) (Ptrend < 0.001), and with severity of the histological lesions from 15.3% (33/216) in Negative to 91.3% (63/69) in patients with cancers (SCC+ADC) (Ptrend < 0.001).